14 Views | 6 Downloads
Catherine Lavau, DVM, PhD*, Research Drive, LSRC building, Room C-243, Box 3813, Durham, NC 27710, Phone: (919) 684 0575 Email: catherine.lavau@duke.edu
Daniel S. Wechsler, MD, PhD*, HSRB W344, 1760 Haygood Dr NE, Atlanta, GA 30322, Phone: (404) 727-3620, Email: dan.wechsler@emory.edu
The authors contributed equally to the manuscript.
None of the authors has any direct or indirect commercial financial incentive associated with publishing this article. None of the authors has an affiliation with any organization that, to our knowledge, has a direct interest in the subject matter discussed. The Wechsler Laboratory received financial support from Karyopharm, Inc. several years prior to performing the work described in this manuscript, but no Karyopharm products were used for the studies described here.
This work was supported by an American Society of Hematology Research Training Award for Fellows (WKA), Hyundai Hope on Wheels Young Investigator Award (WKA and CPL), Hyundai Hope On Wheels Scholar Award (CPL and DSW), the Duke Cancer Institute (CPL), a NIH R03 grant (1R03CA191983–01A1, CPL), Alex’s Lemonade Stand Young Investigator Award (JLH), Pablove Foundation (JLH), Pediatric Cancer Research Foundation (JLH), NHLBI T32 5T32HL007057–37 (WKA), NHLBI T32 5T32HL007057–40 (SKS), a St. Baldrick’s Foundation Research Award (DSW), and the Schiffman Family Foundation. CPL is an INSERM scientist.
CRM1 plasmids containing mutants in the NUP214 binding region were generously provided by Ralph Kehlenbach and Sarah Port. Pritha Bagchi, PhD and the Emory Integrated Proteomics Core provided assistance with BioID2 Mass Spectrometry.